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Cell morphologyRecent studies have demonstrated that the actin binding protein, ezrin, and the cAMP-sensor, EPAC1, cooperate to
induce cell spreading in response to elevations in intracellular cAMP. To investigate the mechanisms underlying
these effects we generated a model of EPAC1-dependent cell spreading based on the stable transfection of
EPAC1 into HEK293T (HEK293T–EPAC1) cells. We found that direct activation of EPAC1 with the EPAC-selective
analogue, 8-pCPT-2′-O-Me-cAMP (007), promoted cell spreading in these cells. In addition, co-activation of
EPAC1 and PKA, with a combination of the adenylate cyclase activator, forskolin, and the cAMP phosphodiesterase
inhibitor, rolipram, was found to synergistically enhance cell spreading, in association with cortical actin bundling
and mobilisation of ezrin to the plasma membrane. PKA activation was also associated with phosphorylation of
ezrin on Thr567, as detected by an electrophoretic bandmobility shift during SDS-PAGE. Inhibition of PKA activity
blocked ezrin phosphorylation and reduced the cell spreading response to cAMP elevation to levels induced by
EPAC1-activation alone. Transfection of HEK293T–EPAC1 cells with inhibitory ezrin mutants lacking the key PKA
phosphorylation site, ezrin-Thr567Ala, or the ability to associate with actin, ezrin-Arg579Ala, promoted cell
arborisation and blocked the ability of EPAC1 and PKA to further promote cell spreading. The PKA phospho-
mimetic mutants of ezrin, ezrin-Thr567Asp had no effect on EPAC1-driven cell spreading. Our results indicate
that association of ezrin with the actin cytoskeleton and phosphorylation on Thr567 are required, but not sufﬁ-
cient, for PKA and EPAC1 to synergistically promote cell spreading following elevations in intracellular cAMP.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Cyclic adenosine monophosphate (cAMP) is a ubiquitous second
messenger that is involved in regulating many aspects of cell function,
including cell differentiation [1], secretion [2], cell morphology [3], in-
ﬂammatory pathways [4], contractility [5] and synapse formation [6].
Elevations in intracellular cAMP occur in response to activation of Gs-
coupled G-protein coupled receptors (GPCRs). GPCRs, in turn, activateivated by cAMP; ROCK, RhoA
manumbilical vein endothelial
oesin family; FERM, 4.1 ezrin–
CPT-2′-O-Me-cAMP; F-Actin,
Cellular and Systems Biology,
QQ, UK. Tel.: +44 1413303908.
Yarwood).
. This is an open access article underadenylate cyclase (AC), which catalyses the conversion of ATP into
cAMP. This process is terminated through the action of the cAMP phos-
phodiesterase (PDE) family, which hydrolyses cAMP to 5′-AMP [7].
Elevated cAMP levels promote the activation of a select range of in-
tracellular effectors, including exchange protein activated by cAMP
(EPAC) [8,9] and protein kinase A (PKA) [10], which both contain cyclic
nucleotide binding domains (CNBDs) [11]. In the case of PKA, cAMP
binding to regulatory CNBDs promotes their dissociation from the cata-
lytic subunit, thereby facilitating the phosphorylation of a plethora of
downstream signalling proteins [12]. EPACs are also activated by
cAMP binding, although their mechanism of activation and catalytic ac-
tivity are strikingly different from PKA [8,9]. Indeed, the regulatory
CNBD and catalytic regions of the two principle EPAC isoforms, EPAC1
and EPAC2, are contained within a single gene product, and regulation
is imparted by an interaction between anN-terminal regulatory domain
and C-terminal catalytic domain [13]. Moreover, active EPAC acts as athe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Rap1 and Rap2 [14], as opposed to the kinase activity of PKA [10].
A large body of evidence points toward a role for EPAC1–Rap1 sig-
nalling in governing cAMP-regulated cell shape, spreading and mor-
phology [4,15]. Furthermore, EPAC1/Rap1 signalling has been linked
to the promotion of barrier protective functions in the vascular endo-
thelium, through the regulation of adhesive and cohesive pathways
linked by the dynamic cytoskeleton [16,17]. These effects are largely at-
tributed to the re-localisation of vascular endothelial-speciﬁc VE-
cadherin [18] and the regulation of cytoskeletal elements [19,20]. In
particular, cytoskeletal reorganisation occurs [20,21] through Rap1-
mediated regulation of the Rho GTPase family of cytoskeletal regulators
[18,22,23]. However, many of these EPAC1-regulated pathways
synergise with PKA for maximal effect, which may be dependent of
the involvement of the ezrin–radixin–moesin (ERM) protein family
member, ezrin [3].
ERMproteins are a homologous group of actin binding proteinswith a
characteristic N-terminal 4.1-ezrin–radixin–moesin (FERM)domain [24],
which control a wide range of cellular processes through their role as
scaffold between the actin cytoskeleton and the plasma membrane lipid
component, phosphoinositol-4,5-bisphosphate (PIP2) [25]. The impor-
tance of ezrin in EPAC1/Rap1-mediated cell spreading has been demon-
strated using siRNA-mediated knockdown of ezrin, which severely
limits cell spreading in response to elevations in intracellular cAMP [3].
The activity of ezrin appears to be modulated by multiple proteins ki-
nases, which act through phosphorylation of Ser66 [26], Tyr81 [27],
Tyr145, Tyr353 [28] and Tyr477 [29]. However, it is Thr567 phosphoryla-
tion that has been identiﬁed as being key in relieving an auto-inhibitory
head to tail conformation within ezrin, thereby facilitating activation
[25,30]. Interestingly, phosphorylation of ezrin on Thr 567 has been re-
ported to occur in response to cAMP elevation, through activation of
PKA [31]. In this respect, ezrin may therefore serve to coordinate the ac-
tions of EPAC1 and PKA towards the regulation of cell spreading andmor-
phological change. Herewe investigate the role of ezrin in controlling the
morphological response of cells to PKA and EPAC1 activation in a cell
model of EPAC1-dependent cell spreading.
2. Materials and methods
2.1. Reagents
Forskolin and Y27642 were purchased from Merck, UK. 8(4-
chlorophenylthio)-2′-O-methyl-cAMP (007) was purchased from
Biolog Life Sciences (Bremen, Germany). H-89 was from Sigma-
Aldrich and 4′, 6-diamidino-2-phenylindole (DAPI) from Invitrogen.
Generation of HA-EPAC1 and CMV-myc-EPAC1-FLAG has been de-
scribed [37]. pCAsalFLAG-GFP (GFP) was a generous gift from Professor
Gwyn Gould, University of Glasgow, UK. pLV-CMV-ezrin-GFP and pLV-
CMV-ezrinT567D-GFP were kind gifts from Professor Johannes Bos,
University of Utrecht, Netherlands. p-eGFP-ezrin-T567Awas a generous
gift from Sabrina Marion, Institut Cochin, Paris, France.
2.2. Antibodies
The primary antibodies used were anti-EPAC1 (Clone 5D3,
#4155; New England Biolabs; Ipswich, UK) and anti-ezrin (Santa
Cruz Technologies, California, USA). Anti-Myc (#9E10), M2
monoclonal Flag (#F3165), anti-HA (#H9658) and anti-GFP were
purchased from Sigma-Aldrich. InfraRed secondary antibodies (don-
key anti-rabbit/anti-mouse 680 nm (#926-32213) and 700 nm
(#926-32212)) were from Licor Biosciences (Nebraska, USA) and
were imaged using the ODYSSEY® Sa Infrared Imaging System. Fluo-
rescent secondary antibodies used for confocal imaging were Alexa-
Fluor goat anti-rabbit/anti-mouse 488 nm and 568 nm (Alexa-Fluor,
Invitrogen). Rhodamine Phalloidin was purchased from Invitrogen
(Paisley, UK).2.3. Cell culture
Human Embryonic Kidney (HEK293T) cell lines stably expressing ei-
ther 3xFLAG-myc-CMV-26 vector (Sigma-Aldrich, UK) containing full-
length human EPAC1, or vector alone, were prepared by Dundee Cell
Products (Dundee, UK). COS1 and HEK293T cells were grown in
Dulbecco's modiﬁed Eagle's medium (DMEM) 10% (v/v) foetal bovine
serum (Sigma-Aldrich, UK), 2% (v/v) glutamine (Sigma-Aldrich, UK)
and 2% (v/v) penicillin/streptomycin (Sigma-Aldrich, UK) and incubat-
ed at 37 °C in 5% (v/v) CO2. Selection of stable cell lines was maintained
through addition of 400 μg/ml G418 (Sigma-Aldrich, UK) to the cell cul-
ture medium. Human umbilical cord endothelial cells (HUVECs) were
grown in Endothelial Growth Medium MV2, supplemented with the
MV2 supplement pack (Promocell, Heidelberg, Germany) and 1% (v/v)
penicillin/streptomycin. Experiments using HUVECs were performed
between Passages 1 and 6.
2.4. Cell transfection
Cells were grown to 50% conﬂuence on ethanol sterilised Ø13 mm
glass coverslips (for confocal analysis) or in 10 cm2 plates (for western
blotting experiments). DNA constructs were then transfected into cells
using Lipofectamine 2000 (Life Technologies; #116668-027) as per
the manufacturer's instructions.
2.5. Immunoﬂuorescent confocal microscopy
Cells were seeded at a density of 2 × 105 on ethanol sterilised
Ø13 mm glass coverslips and allowed to adhere overnight. Cells were
then transfected as described and then stimulated with the indicated
treatments prior to ﬁxation with ﬁxing buffer (3% (w/v) paraformalde-
hyde, 1% (w/v) sucrose, 1 mM CaCl2, 1 mMMgCl2 in PBS (37 mMNaCl,
2.7 mM KCl, 8 mM Na2HPO4, 1.46 mM KH2PO4, pH 7.4)). Coverslips
were then quenched for 10 min in 50 mMNH4Cl in PBS, permeabilised
for 4 min with 0.1% (v/v) Triton X-100 in PBS and then blocked with
0.02% (v/v) goat serum in 0.02% (w/v) ﬁltered ﬁsh skin gelatine in
PBS. Primary and secondary antibodies (anti-mouse/anti-rabbit FITC/
rhodamine conjugates or rhodamine–phalloidin for actin stained
cells) were incubated for 1 h at room temperature. Nuclei were
visualised with 4′, 6-diamidino-2-phenylindole (DAPI, 10 μg/ml) or
REDDOT (Cambridge Bioscience; #40061) for 20min at room tempera-
ture. Coverslips were washed 3 times in block buffer between incuba-
tions. Coverslips were then mounted onto glass slides using Shandon
Immu-Mount (Thermo Fisher Scientiﬁc, UK) and visualised using a
63× Zeiss oil immersion objective, on a Zeiss confocal microscope
(Carl Zeiss, Germany). Alexa Fluor® dyes (488 nm) and GFP fusion pro-
teins were excited with an argon laser whereas 568 nm Alexa Fluor®
dyes and rhodamine phalloidin were excited with a helium neon
laser. Zeiss Pascal software was used to collect images, which were
saved in the LSM ﬁle format and analysed using ImageJ software
(http://rsbweb.nih.gov/ij/). For morphology assessments ImageJ wand
tool was used to select cells from images. These were then measured
for area and perimeter.
2.6. Förster Resonance Energy Transfer (FRET) measurements
For FRET experiments HEK293T cells stably transfected to express
the EPAC-CAMP FRET sensor [32] were transferred into a modiﬁed
Tyrode solution (140 mM NaCl, 3 mM KCl, 2 mM MgCl2, 2 mM CaCl2,
15 mM glucose, 10 mM HEPES, pH 7.2). To allow for adaptation to
these new conditions, the cellswereﬁrst kept for 10min in a cell culture
medium/Tyrodemix (33/66%), before theywere ﬁnally transferred into
the Tyrode solution. All applied substances were premixed into 150 μl
Tyrode solution before addition to the cells. FRET measurements were
performed with a Nikon Eclipse FN-1, equipped with an Opto-Led ﬂuo-
rescent light source (Cairn-research), a Dual-View beam-splitter
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were acquired with a 40×/0.8 numerical aperture long distance water
dipping objective (Nikon). Excitation wavelength was 536 ± 25 nm,
excitation/emission dichroic was 455 nm long pass. Emission light
was splitted by a 505 nm longpass dichroic and ﬁltered at 480 ±
15 nm for CFP emission and 535± 20 nm for YFP emission. Acquisition
and analysis was performed using Optoﬂuor (Cairn Research), which is
identical to Metaﬂuor (Molecular Devices). To reduce cell stress by illu-
mination, long term experiments were performed at binning 2, which
reduces the image resolution but increases signal intensity. All curves/
values are background-subtracted and corrected for drifting baselines.
2.7. Dynamic mass redistribution assay
Wild type HEK293T-vector and HEK293T–EPAC1 cells were plated at
10,000 cells/well in 30 μl growth media on a corning Epic 384 well cell
assay microplate (PerkinElmer), and then incubated overnight at 37 °C.
Cellswere then equilibrated for 2 h at room temperature and then a base-
line measurement was recorded using an Enspire plate reader. The cells
were then treated with varying concentrations of the EPAC1 antagonist,
ESI-09 (Sigma Aldrich) or the PKA inhibitors, H-89 (Tocris) or KT5720
(Tocris), in the presence or absence of forskolin (Tocris) and rolipram
(Tocris) or 007-(8-pCPT-O′-Me-cAMP) (Biolog). Dynamic mass redistri-
bution measurements (DMR) were then taken every minute for
60min. All treatments were made up in DMSO (Fisher Scientiﬁc) and di-
luted in 1× HBSS (Life Technologies)/20 mM HEPES (Sigma Aldrich)
assay buffer. For data analysis DMR readings from HEK293T-vector cells
were subtracted from HEK293T–EPAC1 cells.
2.8. Western blotting
Cells were washed twice with ice cold PBS, lysed in ice cold lysis
buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1% (v/v) Triton X-100,
0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 10 mM sodium ﬂuo-
ride, 5 mM EDTA, 10 mM sodium phosphate) with protease inhibitor
cocktail (Roche) and then cell debris was removed by centrifugation
at 13,000 ×g for 20 min. The bicinchoninic acid assay [38] was then
used to assess protein concentration of cleared lysates. Equal protein
amounts were loaded and then separated on 7% and 12% (w/v) SDS
PAGE gels and then transferred to nitrocellulose membranes with
equal protein loading veriﬁed by Ponceau S staining. Membranes were
then incubated for 1 h in block buffer (1% (w/v) skimmed milk powder
in TBST (50 mM Tris, 150 mM NaCl, 0.05% (v/v) Tween 20)). Mem-
branes were then incubated with primary antibodies at 4 °C overnight
followed by incubation with InfraRed (donkey 700 nm and donkey
800 nm) secondary conjugated antibodies for 1 h at room temperature.
InfraRed secondary antibodies were visualised using the ODYSSEY® Sa
Infrared Imaging System (Licor Biosciences, Nebraska, USA).
2.9. Statistical analyses
Statistical signiﬁcance was determined using one-way analysis of
variance (ANOVA) with Tukey post-test.
3. Results
3.1. EPAC1 and PKA cooperate to promote cell spreading
To conﬁrm previous observations that activation of endogenous EPAC
can control cell spreading [3,18,33,34], COS1 and HUVECs, both of which
express EPAC1, were stimulated with a combination of the adenylate cy-
clase (AC) activator, forskolin, and the type 4 phosphodiesterase inhibitor,
rolipram (F/R), to elevate intracellular levels of cAMP. Additionally the
EPAC selective cAMP analogue 8-pCPT-2′-O-Me-cAMP (007) [35] was
employed in order to assess the speciﬁc role of EPAC over PKA. Treatment
of COS1 (1 h) or HUVECs (2 h) with either F/R or 007 led to signiﬁcantincreases in cell size (Supplementary Figs. 1 and 2). The ability of 007 to
induce cell spreading indicates that endogenous EPAC activation is sufﬁ-
cient to promote cell spreading in both cell lines. However, in contrast
to what was observed in COS1 cells, there was signiﬁcantly more cell
spreading observed in HUVECs stimulated with F/R than 007 (Supple-
mentary Fig. 2B). Furthermore, the enhanced cell spreading promoted
by F/R coincided with a signiﬁcant redistribution of actin into cortical
actin bundles at the cell periphery, an effect that was not observed in
007-stimulated HUVECs (Supplementary Fig. 2C). This suggests that
EPAC1 activation alone is not sufﬁcient to promote maximal levels of
cell spreading or cortical actin bundling in HUVECs, and that there is an
additional requirement for PKA. Therefore cooperativity must exist be-
tween EPAC and PKA signalling pathways in HUVECs that underlies the
cytoskeletal reorganisation required for maximal cell spreading.
To investigate this cooperativity further we generated a HEK293T cell
line that stably expresses myc- and FLAG-tagged EPAC1 or vector alone.
We found that HEK293T–EPAC1 cells, but not vector-containing cells,
responded to the cAMP-elevating agents, prostaglandin E2 (PGE2) and
F/R, and 007with a signiﬁcant increase in cell spreading (Fig. 1). Interest-
ingly, as observed with HUVEC cells, cortical actin bundling occurred in
response to PGE2 and F/R treatment, but not 007, in HEK293T–EPAC1,
but not vector-only cells (Fig. 1). This suggests that there is a fundamental
requirement for EPAC1 for cAMP-promoted cell spreading and cortical
actin bundling in these cells. Moreover, although EPAC1 activation pro-
motes cell spreading it is not sufﬁcient to promote actin bundling, impli-
cating an additional role for PKA in producing these effects.
EPAC1 and PKAhave been observed to act synergistically to promote
a range of cellular processes [36–40]. In order to testwhether PKA coop-
erates with EPAC1 to promote cell spreading, HEK293T–EPAC1 cells
were treatedwith 007 and F/R, in the presence or absence of the PKA in-
hibitor, H-89 [41]. We found that H-89 treatment had no effect on basal
cell area or cell spreading induced by 007 (Fig. 2). However, cell spread-
ing in response to F/R was signiﬁcantly reduced to levels comparable
with 007 stimulation, following H-89 treatment (Fig. 2B). This indicates
that cooperativity exists between PKA- and EPAC1-regulated signalling
pathways to promote maximal cell spreading following cAMP stimula-
tion of HEK293T cells.
It should be noted, however, that when wemeasured EPAC1 activa-
tion in HEK293 cells (Supplementary Fig. 3) or SK-N-SH cells (results
not shown), following stimulation with either 007 or F/R, we ﬁnd that
F/R always promotes a signiﬁcantly greater degree of EPAC1 activation
than 007 alone (Supplementary Fig. 3), suggesting that the larger in-
creases in EPAC1 activation promoted by F/Rmyunderlie the associated
enhancement of cell spreading (Fig. 2). However, our data supports the
idea that cell spreading is, in the ﬁrst instance, EPAC1-dependent, as
demonstrated in HEK293T–EPAC1 cells compared to HEK293-vector
cells as seen in Fig. 1, and that the enhanced cell spreading seen with
F/R treatment being attributable to PKA activation (Fig. 2).
It should be noted, however, that the PKA inhibitor, H-89, has been
reported to have a number of off-target effects, including inhibition of
PKC, ERK and AKT signalling pathways [42]; we therefore sought to de-
termine the role of these kinases in controlling EPAC1-dependent cell
spreading. A direct link between EPAC mediated signalling and AKT ac-
tivation has been reported to control cytoskeletal reorganisation and
adhesion in mesenchymal stem cells [43]. We therefore used the inhib-
itor of AKT activation, LY294002, to test the requirement for AKT in
EPAC1-dependent cell spreading. Although 10 μM LY294002 effectively
inhibited insulin-induced phosphorylation of AKT at a site indicative of
activation (Ser 473) in EPAC1–HEK293 cells (Supplementary Fig. 4), it
was unable to affect cAMP induced cell spreading in response to F/R in
the same cells (Supplementary Fig. 4A and B). Similarly, EPAC1 activa-
tion has, controversially, been associated with activation of the ERK,
MAPK cascade [15,43,44]. Indeed, we found that cAMP elevation with
F/R is sufﬁcient to induce ERK phosphorylation (Thr202/Tyr204) in
HEK293T–EPAC1 cells (Supplementary Fig. 5C). Despite being activated
in response to cAMP, inhibition of ERK activity with the MEK inhibitors,
Vector Myc
-EPAC1-
FLAG
Antibody: EPAC1 (5D3) myc
Transfection: Vector Myc
-EPAC1-
FLAG
HEK293A
B
C
Fig. 1. EPAC1 is required for cell spreading and cytoskeletal reorganisation inHEK293T cells. A) Cell extractswere prepared fromHEK293T cells that had been stably transfectedwith either
vector alone or myc- and FLAG-tagged EPAC1. Extracts were then immunoblotted with either anti-EPAC1 (left) or anti-myc antibodies (right). B) HEK293T–EPAC1 and HEK293T-vector
cells were stimulatedwith either 007, prostaglandin E2 (PGE2) or F/R (10 μM, 60′) and then F-actinwas visualisedwith rhodamine phalloidin. Arrows indicate actin polymerisation at the
cell periphery. C) Cell areas were calculated from 10 random cell images (displayed as mean of 3 independent experiments ±SEM). *** = P b 0.001 (two way ANOVA).
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dependent cell spreading (Supplementary Fig. 5A and B) indicating
that although ERK is a downstream target for cAMP signalling this oc-
curs independently to the changes in cell morphology associated with
activation of EPAC1. This idea is supported by our observation that con-
ventional (cPKC) and novel (nPKC) PKC isoforms are also not required
for EPAC1-dependent cell spreading (Supplementary Fig. 6). We had
previously reported that the activity of cPKCα and nPKCδ isoforms are
required for EPAC1-dependent activation of gene expression in COS1
cells [45] and cyclic AMP-dependent ERK activation in HUVECs [46].
However it appears that these PKC isoforms do not play a role inEPAC1-promoted cell spreading in HEK293 cells. Accordingly activation
of cPKCs and nPKCs, following treatment of EPAC1–HEK293 cells with
100 nM of the phorbol ester, PMA, lead to cell shrinkage, rather than
spreading, and this was reversed by the PKC inhibitors Gö-6983 and
Bisindolymaleimide I (Supplementary Fig. 6A and B). Hence, although
PKC isoforms appears to play a role in controlling cell morphology in
HEK293 cells, this appears to be mechanistically distinct from the
changes induced following EPAC1 activation. In conclusion, it appears
that cell spreading in response to cAMP elevation occurs independently
of effects on AKT, ERK and PKC signalling and that it is unlikely that the
actions of the inhibition H-89, on the suppression of cell F/R-induced
AC
B
Fig. 2. PKA inhibition inhibits cAMP but not EPAC1-mediated cell spreading. A) HEK293T–EPAC1 cells were pre-incubated with the PKA inhibitor H-89 (10 μM, 30′) and then stimulated
with either F/R or 007 (10 μM, 60′). Cells were then probed usingα-ezrin antibodies (white) to detect the cell body. B) Cell areas were calculated from 10 randomly acquired images and
mean cell area from three independent experiments are shown (±SEM). Signiﬁcance is indicated ***, p b 0.001, relative to diluent-treated cells, and #, p b 0.05, for H-89-treated cells,
relative to F/R-treated cells. C) HEK293T–EPAC1 cells were stimulated with 6Bnz-cAMP (10 μM, 60′), 007 (10 μM, 60′) or F/R. Cell areas were then calculated from 10 images and
mean cell area±SEM (n=3) is presented as a histogram. Signiﬁcant increases in cell area relative to diluent-treated control cells are indicated, ***, p b 0.001, as are signiﬁcant differences
between 007- and 6-Bnz-cAMP-treated cells (###, p b 0.001).
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acting through inhibition of PKA.
Therefore, to provide further evidence that cell spreading is responsive
to PKA activation in EPAC1 transfected cells, we stimulated cells with the
PKA-selective agonist, N(6)-Benzoyl-cAMP (6Bz-cAMP), and measured
cell spreading. We found that 6Bz-cAMP promoted a signiﬁcant increase
in cell spreading, which was signiﬁcantly lower that the extent of cell
spreading inducedby007andF/R (Fig. 2C). This demonstrates that specif-
ic activation of PKA can promote cell spreading in EPAC1 expressing cells,
althoughmaximal induction of cells spreading is exerted by concomitant
activation of PKA and EPAC1 in these cells, as occurswith F/R stimulation.
We next examined the relationship between PKA and EPAC1 in the
control of cell morphology by using an independent measure of cell
spreading by measuring dynamic mass redistribution of cells (DMR)
in response to pharmacological stimulation (Supplementary Fig. 7).
This involved the use of Corning Epic technology to measure EPAC1-dependent cell-spreading, namely, the ﬂattening and broadening of
the cell as the cytoskeleton is redistributed closer to the plate. In all ex-
periments the level of cell spreading detected in cell expressing vector
alone served as a baseline to cell spreading in EPAC1-expressing cells.
We found that stimulation of cells for up to 60 min induced a clear in-
crease in DMR in both 007 and F/R-treated cells, however the level of
DMR was consistently greater in F/R-treated than 007-treated cells
(Supplementary Fig. 7A). Importantly, inhibition of PKA with H-89, or
a chemically distinct PKA-inhibitor, KT5720, suppressed F/R-promoted
DMR(Fig. 3A), butwere not inhibitory in 007-stimulated cells and (Sup-
plementary Fig. 7B and C). Moreover, the chemical inhibitor of EPAC ac-
tivation, ESI-09, was also effective at inhibiting F/R-induced DMR
(Supplementary Fig. 7A). Together these experiments indicate that
maximal F/R-stimulated mass redistribution associated with cell
spreading in HEK293T–EPAC1 cells is dependent on activation of both
EPAC1 and PKA signalling routes by cAMP.
BC
A
Fraction:
Transfection:
α - ezrin
α - GFP
α - actin
P     S       P     S        P      S       P     S       P     S
None GFP GFP-
ezrin
WT
GFP-
ezrin
T567D
GFP-
ezrin
T56A
69kDa
96kDa
Fig. 3. PKA activation promotes post-translationalmodiﬁcation of ezrin. A)HEK293T–EPAC1
and HEK293T-vector cells were stimulated with F/R, as indicated, and then particulate frac-
tions were prepared from cells and immunoblotted with anti-ezrin and anti-Epac1 antibod-
ies. Arrows indicate the position of putative ezrin phospho-forms. Immunoblots are
representative of an experiment done on 3 separate occasions. B) HEK293T–EPAC1 cells
were pre-treatedwithH-89 (10 μM,30′) and then stimulatedwith 007 and F/R, as indicated.
Particulate cell fractions were then prepared and probed with anti-ezrin antibodies.
Immunoblots are representative of an experiment done on 3 separate occasions. C) HEK-
293T–EPAC1 was transfected with GFP-tagged wild type (WT), phospho-mimetic (T567D)
and phospho-null mutants (T567A) of ezrin. Cells were then harvested and then separated
into pellet and soluble fractions as described in the Materials and methods. Cell extracts
were then immunoblotted with the indicated antibodies. Immunoblots are representative
of an experiment done on 3 separate occasions.
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cAMP-elevation in HEK293T–EPAC1 cells
Results indicate that EPAC1-dependent mechanisms exist in
HEK293T cells that allow the coordinated action of EPAC1- and PKA-
activation to promote cell spreading and cortical actin bundling. One
protein candidate for this integration of signalling is the actin cytoskele-
tal linker, ezrin, which has been shown to be essential for EPAC1-
mediated cell spreading [3] and also for anchoring of PKA [47,48].
Ezrin also plays a central role in regulating the formation of the cell cor-
tex and plasma membrane protrusions [47]. Considering this central
role for ezrin in the control of plasmamembrane dynamics and cytoskel-
etal organisation, we next examined whether ezrin is a target of cAMP-
dependent signalling. HEK293T-vector and HEK293T–EPAC1 cells were
treated with F/R and then particulate cell fractions were prepared andimmunoblottedwith anti-ezrin antibodies (Fig. 3A). Two distinct immu-
noreactive bands were detected on immunoblots comprising a lowmo-
lecular weight band, representing ~80% of particulate ezrin, and a high
molecular weight band, representing the remaining ~20% of ezrin pro-
tein. Following cAMP stimulation with F/R the higher molecular weight
band underwent a band-shift, suggesting cAMP-dependent post-
translational modiﬁcation (Fig. 3A). The cAMP-induced band-shift was
observed in both EPAC1- and vector-expressing cells (Fig. 3A), suggest-
ing that post-translational modiﬁcation of ezrin is not speciﬁcally linked
to EPAC1 activity in HEK293T cells, andmore likely to be a result of PKA
activation. Indeed, it has been reported that PKA can regulate ezrin activ-
ity through phosphorylation of Ser66 [26] and Thr567 [31]. To test for a
role of PKA in promoting the ezrin band-shift, cellswere stimulatedwith
007 or F/R in the presence or absence of H-89. We found that EPAC1 ac-
tivation with 007 did not induce a band-shift of Ezrin (Fig. 3B). In con-
trast, F/R provoked a robust band-shift that was ablated by co-
treatment with H-89 (Fig. 3B), indicating that PKA activation is linked
to the post-translational modiﬁcation of ezrin, possibly through phos-
phorylation. It has previously been reported [31], that increases in the
phosphorylation of ezrin on Thr567 in response to elevations in intracel-
lular cAMP. To investigate whether phosphorylation of Thr567 is in-
volved in the band-shift we observed following cAMP elevation we
observed, we transfected HEK293T–EPAC1 cells with GFP-tagged wild
type (WT), phospho-mimetic (T567D) and phospho-null mutants
(T567A) of ezrin (Fig. 3C). We found that WT and phospho-mimetic
GFP-tagged forms of ezrin appear to be constitutively phosphorylated,
as evidenced by a high-molecular weight band-shifted form, whereas
phospho-null ezrin exists as mainly a lower molecular-weight form
(Fig. 3C). In addition, WT and the phospho-mimetic T567D mutant ap-
pear to induce a band-shift of endogenous ezrin in transfected cells,
whereas the phospho-null mutant appears to suppress phosphorylation
of endogenous ezrin (Fig. 3C). These results suggest that phosphoryla-
tion of Thr567 appears to contribute to the upward band-shift of ezrin
following cAMP-stimulation of HEK293T–EPAC1 cells.
3.3. Ezrin is required for cAMP-mediated cell spreading in HEK293T Cells
To further investigate a role for ezrin in coordinating PKA- and
EPAC1-dependent signalling, we investigated the role of cAMP in deter-
mining the sub-cellular distribution of ezrin and other ERM proteins in
HEK293T cells. Immunoﬂuorescent staining with an antibody that de-
tects the ERM family members ezrin, radixin andmoesin demonstrated
an accumulation of ERM immunoreactivity at the cell membrane fol-
lowing F/R-treatment of HEK293T–EPAC1 cells, but not HEK293T-
vector cells (Supplementary Fig. 8), indicating that at least one ERM
family member is responsive to cAMP in an EPAC1-dependent manner
in these cells. Isoform-speciﬁc antibodies were next employed to deter-
minewhich ERM family members were responsive to EPAC1 activation.
Results showed that whereas radixin and moesin maintained a largely
diffuse distribution, regardless of cell line or treatment applied (Supple-
mentary Fig. 8). In contrast, following cAMP stimulation GFP-tagged
ezrin appeared to become more diffuse within the cytosol and at the
membrane, likely due to increased cell area and perimeter associated
with isotropic cell spreading (Fig. 4). The accumulation of GFP-ezrin
protein at the cell periphery, alongside actin, suggests that ezrin may
be linked to cortical actin reorganisation following EPAC1 activation.
Furthermore, the distribution of total ERM (Supplementary Fig. 8) and
ezrin (Fig. 4) at the plasma membrane suggests that ezrin is the
cAMP-responsive ERM protein in HEK293T–EPAC1 cells.
Results indicate that ezrin is phosphorylated by PKA (Fig. 3) and
mobilised to the cell periphery following EPAC1 activation (Fig. 4) in
HEK293T cells. This suggests that ezrin may coordinate PKA- and
EPAC1-dependent signals to control cell spreading. In order to investi-
gate the role of ezrin in the control of cAMP-mediated cell spreading,
HEK293T–EPAC1 cells were transfected with GFP-tagged ezrin-WT or
two inactive mutants of ezrin; ezrin-T567A, which lacks the PKA
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Fig. 4. Ezrin accumulates at the plasma membrane in HEK293T cells. HEK293T–EPAC1
cells were transfected with a vector encoding GFP-tagged wild type ezrin (ezrin-WT-
GFP) that were prepared for immunoﬂuorescence as described in the Materials and
methods. Cellswere then stainedwith anti-actin antibodies and visualised by confocalmi-
croscopy. Results are representative of an experiment done on 3 separate occasions.
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[3], and ezrin-R579A, which has a reduced ability to couple the plasma
membrane to the actin cytoskeleton [48]. Transfection of cells with
ezrin-WT had no discernible effect on cell morphology or the cell-
spreading response of HEK293T–EPAC1 cells following 007 (results
not shown) or F/R treatment (Fig. 5). In contrast, the introduction of
ezrin-T567A and ezrin-R579A mutants into cells produced dramatic
changes in cell morphology, characterised by signiﬁcantly higher cell
perimeters (Fig. 5A), consistent with the formation of membrane pro-
jections (Fig. 5B). Furthermore, the inactive ezrin mutants suppressed
the ability of F/R (Fig. 5A) and 007 (results not shown) to enhance cell
spreading (Fig. 5A). These results indicate that phosphorylation of
ezrin at Thr567 and interactionwith actin are important formaintaining
the basal cell morphology of HEK293T cells and that active ezrin is re-
quired for the subsequent actions of EPAC1 and PKA in the promotion
of cAMP-induced cell spreading.Fig. 5.Dominant negative forms of ezrin induce cell spreading and arborisation inHEK293
cells independently of cAMP. A) HEK293T cells were transfected with GFP-tagged wild-
type (WT) ezrin or dominant-negative ezrin (T567A) and ezrin (R579A) constructs.
Cells were then stimulated with F/R for 60 min. GFP-expressing cells were then imaged
using confocal microscopy and cell areas and perimeters were calculated (5 images per
experiment, N = 3, ±SEM). Signiﬁcant changes relative to diluent-treated cells are
indicated, **, p b 0.01. B) Representative images of treated cells stained with rhodamine
phalloidin.
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cAMP-mediated cell spreading, HEK293T–EPAC1 cells were transfected
with GFP-tagged ezrin-T567D, a PKA phospho-mimetic mutant of ezrin
[25]. We found that ezrin-T567D had no appreciable effect on cell
spreading in response to EPAC1 and PKA activation with F/R (Fig. 6).
This suggests that although phosphorylation of Thr567 is required for
cAMP-induced cell spreading, as demonstrated by use of the T567Amu-
tant (Fig. 5), it is not sufﬁcient. We also investigated whether another
PKA phosphorylation site in ezrin may also be required to promote
cell spreading. In this respect, an additional PKA phosphorylation site
has been identiﬁed in ezrin at Ser66 [26].We found that cells expressing
ezrin-S66D exhibited reduced cell spreading potential (Fig. 6), and is
therefore probably not involved in the promotion of cell spreading by
EPAC1 and PKA reported here. Together these results suggest that the
ability of EPAC1 to promote PKA-dependent cell spreading requires in-
teractions between ezrin and the actin cytoskeleton and basal phos-
phorylation of ezrin at Thr567, but not Ser66.
4. Discussion
Here we show that EPAC1 is absolutely required for cell spreading of
HEK293T cells in response to cAMP stimulation. In addition, co-
stimulation of EPAC1 and PKA with F/R induced further, PKA-dependent
cell spreading and cortical actin bundling, over and above that induced
by EPAC1 alone, indicating a secondary, synergistic effect of PKA on cell
spreading in these cells. We conclude that EPAC1 may therefore gate
the effects of PKA in HEK293T cells, perhaps by redistributing PKA into
membrane rufﬂes, an effect previously observed to facilitate PKA associa-
tion with Rho proteins at the cell surface [49].
In addition to cell spreading, the cooperativity between EPAC1 and
PKA appears to underlie the reorganisation of the actin cytoskeleton fol-
lowing cAMP elevation; thus cortical actin bundling is observed only
when both EPAC1 and PKA pathways are activated in concert. Recently,
the ERM protein ezrin has been implicated as a regulator of EPAC1-
mediated cell spreading [3]. Ezrin is able to regulate cortical actin struc-
tures and membrane dynamics [50] and both PKA and the Rho-
activated kinase, ROCK, are involved in regulating ezrin activity by di-
rect phosphorylation at key activation sites [26,31,51]. We report here
that cAMP promotes PKA-dependent phosphorylation of ezrin in
HEK293T cells. Although only a small fraction of total cellular ezrin
was observed to undergo a band-shift, this is in agreement with previ-
ous reports suggesting that rapid turnover prevents the accumulation
of ezrin phospho-forms [31]. We found that inhibition of ezrin phos-
phorylation at the PKA-target site, Thr567, or inhibition of ezrin interac-
tionwith the actin cytoskeleton had striking effects on cell morphology.
This was associated with a large increase in the basal perimeter, consis-
tent with the formation of multiple projections from the cell. Despite
promoting an increase in cell area (Fig. 5A), this appeared to be due to
contributionsmade by cell projections (Fig. 5B), rather than the uniform
isotropic spreading observed in response to EPAC1 activation (Fig. 1).
Indeed, the similarity in cell responses to the phospho-null ezrin mu-
tant, ezrin-T567A, and the actin binding mutant, ezrin-R579A, in
terms of cell morphology, suggest that cells expressing ezrin-T567A
may no longer be able to form stable membrane–actin linkages. Indeed
earlier reports have suggested that active ezrin plays a role in stabilising
the plasma membrane and regulating the formation of cell projections
[48]. The requirement for PKA-phosphorylation on ezrin-Thr567 for ef-
fective cAMP-promoted cell spreading (Fig. 3) suggests that EPAC1Fig. 6. Effects of phospho-mimetic forms of ezrin on cAMP-promoted cell spreading. A)
HEK293T cells were transfected with GFP-tagged ezrin-WT or phospho-mimetic forms
of ezrin, ezrin-T567D and ezrin-S66D. Cells were then stimulated for 60 min with F/R.
GFP-expressing cells were then imaged using confocal microscopy and cell areas and pe-
rimeters were calculated (5 images per experiment, N = 3, ±SEM). Signiﬁcant changes
relative to diluent-treated cells are indicated, **, p b 0.01 and ***, p b 0.001, as are signiﬁ-
cant changes relative to F/R-treated, ezrin-T567D cells. B) Representative images of treat-
ed cells stained with rhodamine phalloidin.
1757E. Parnell et al. / Biochimica et Biophysica Acta 1853 (2015) 1749–1758requires PKA-promoted stabilisation of ezrin-regulated cell projections
in order to mediate morphological change. An additional point to note
is that ezrin has been reported to serve as an anchoring protein that re-
cruits PKA to lipid rafts [52]. The recruitment of PKA by ezrin also ap-
pears to require Thr567, since the T567A mutant, but not the T567D
mutant, is impaired in its ability to interact with the R1 regulatory sub-
unit of PKA [52]. In the context of the current study it is difﬁcult to ascer-
tain the importance of this observation for the control of cell spreading,
however it is clear that the increase in basal cell area promoted by inhi-
bition of Thr567 phosphorylation reported here (Fig. 5) may also be
linked to impaired intracellular targeting of PKA. Although it should be
pointed out that the T567D mutant did not affect cell spreading in
HEK293T–EPAC1 cells (Fig. 6), whereas this mutant should still retain
the capacity to interact with PKA and, therefore, targeting of PKA by
ezrin, at least to lipid rafts. Targeting of PKA by ezrin may therefore
not impact greatly on the control of cell spreading by EPAC1, as reported
here.
Overall, we propose that ezrin is involved in the cell spreading re-
sponse of HEK293T–EPAC1 cells following cAMP stimulation by promot-
ing isotropic growth through the stabilisation of the cell membrane and
limiting actin rich projections. PKA appears to regulate this function by
promoting Thr567 phosphorylation and the accumulation of ezrin at
actin rich membrane rufﬂes subsequent to EPAC1 activation. In this re-
gard ezrin has been shown to affect Rho GTPase signalling by anchoring
it to cell projections (Ivetic and Ridley, 2004). In agreement with this
wehave found that inhibition of ROCK, inhibits cell spreading in response
to F/R treatment of HEK293T–EPAC1 cells (Supplemental Fig. 9), suggest-
ing a possible link between EPAC1, PKA-promoted ezrin distribution and
ROCK activity in the promotion of maximal cell spreading by cAMP.
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